½ÃÀ庸°í¼­
»óǰÄÚµå
1593904

¸²ÇÁºÎÁ¾ Áø´Ü ½ÃÀå : ±â¼ú, Áúȯ, ÃÖÁ¾ »ç¿ëÀÚº° - ¼¼°è ¿¹Ãø(2025-2030³â)

Lymphedema Diagnostics Market by Technology (Bioimpedance Analysis, Computed Tomography, Lymphoscintigraphy), Disease (Cancer, Cardiovascular Disease, Inflammatory Diseases), End User - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 192 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

¸²ÇÁºÎÁ¾ Áø´Ü ½ÃÀåÀº 2023³â¿¡ 3,248¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú½À´Ï´Ù. 2024³â¿¡´Â 3,546¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, CAGR 9.26%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 6,040¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸²ÇÁºÎÁ¾ Áø´ÜÀº ¸²ÇÁ¾×ÀÌ ÃàÀûµÇ¾î ½Åü Á¶Á÷ÀÌ ºñÁ¤»óÀûÀ¸·Î ºÎÇ®¾î ¿À¸£´Â °ÍÀ» Ư¡À¸·Î ÇÏ´Â ¸²ÇÁ°è ±â´É Àå¾Ö¸¦ ½Äº°ÇÏ°í Æò°¡ÇÏ´Â µ¥ »ç¿ëµÇ´Â ´Ù¾çÇÑ ¹æ¹ýÀ» Æ÷ÇÔÇÕ´Ï´Ù. ÀÌ ½ÃÀåÀÇ ¹üÀ§´Â ¿µ»ó °Ë»ç(ÃÊÀ½ÆÄ, MRI), »ýü ÀÓÇÇ´ø½º ºÐ±¤¹ý, ¸²ÇÁ ½ÅƼ±×·¡ÇÇ¿Í °°Àº ±â¼úÀ» Æ÷°ýÇÏ´Â ±¤¹üÀ§ÇÑ ½ÃÀåÀÔ´Ï´Ù. ÀÌ·¯ÇÑ Áø´ÜÀÇ Çʿ伺Àº ¾Ï Ä¡·á, ºñ¸¸ ¹× °í·ÉÈ­·Î ÀÎÇØ ¸²ÇÁ ºÎÁ¾ÀÇ À¯º´·üÀÌ Áõ°¡Çϰí È¿°úÀûÀÎ °ü¸®¸¦ À§ÇØ Á¤È®Çϰí Á¶±â Áø´ÜÀÌ ÇÊ¿äÇϱ⠶§¹®ÀÔ´Ï´Ù. ÃÖÁ¾ ¿ëµµ¿¡´Â º´¿ø, Áø´Ü¼¾ÅÍ, ÀçÅà °£È£ ÇöÀå µî ´Ù¾çÇÑ ÀÀ¿ë ºÐ¾ß°¡ ÀÖ½À´Ï´Ù. ½ÃÀåÀ» À̲ô´Â ÁÖ¿ä ¼ºÀå ¿äÀÎÀ¸·Î´Â Áø´Ü ±â¼úÀÇ ¹ßÀü, ÀÇ·á¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡, ÀÇ·á ½Ã¼³¿¡ ´ëÇÑ Á¢±Ù¼º Çâ»ó µîÀÌ ÀÖ½À´Ï´Ù. AI¿Í ¸Ó½Å·¯´×À» ÅëÇÕÇØ Áø´Ü Á¤È®µµ¸¦ ³ôÀ̰í, ƯÈ÷ ÀçÅÃÀÇ·á ÇöÀåÀ̳ª ÀÇ·á ÀÎÇÁ¶ó°¡ ºÎÁ·ÇÑ Áö¿ª¿¡ ÀûÇÕÇÑ È޴뼺°ú »ç¿ë ÆíÀǼºÀ» °®Ãá ±â±â¸¦ °³¹ßÇÒ ¼ö ÀÖ´Â ºñÁî´Ï½º ±âȸ°¡ Á¸ÀçÇÕ´Ï´Ù. ±â¾÷µéÀº Áø´Ü ¼Ö·ç¼ÇÀÇ Çõ½ÅÀ» À§ÇØ ±â¼ú ±â¾÷°úÀÇ Á¦ÈÞ¸¦ ¸ð»öÇϰí, ¿ø°Ý ÀǷḦ Ȱ¿ëÇÏ¸é ´õ ³ÐÀº ½ÃÀåÀ¸·Î ÁøÃâÇÒ ¼ö ÀÖÀ» °ÍÀÔ´Ï´Ù. ±×·¯³ª °í°¡ÀÇ Ã·´Ü Áø´Ü Àåºñ, Áø´Ü ¹æ¹ýÀÇ Ç¥ÁØÈ­ ºÎÁ·, ¼÷·ÃµÈ ÀÇ·á Àü¹®°¡ ¼ö ºÎÁ· µîÀÇ ¹®Á¦´Â ½ÃÀå È®´ë¿¡ Å« °É¸²µ¹ÀÌ µÇ°í ÀÖ½À´Ï´Ù. ½ÃÀåÀº ¶ÇÇÑ Áø´Ü ¹æ¹ýÀÇ ¾ÈÀü¼º°ú À¯È¿¼º¿¡ ´ëÇÑ ±ÔÁ¦ ´ç±¹ÀÇ °¨µ¶¿¡ Á÷¸éÇØ ÀÖ½À´Ï´Ù. ±â¼ú Çõ½ÅÀÇ °¡Àå ÁÁÀº ºÐ¾ß´Â °³ÀÎ ¸ÂÃãÇü ÀÇ·á Á¢±Ù¹ý, ºñħ½ÀÀû Áø´Ü Á¤È®µµ Çâ»ó, Áö¼ÓÀûÀÎ ¸ð´ÏÅ͸µÀ» À§ÇÑ ¼¾¼­ ¹× ¿þ¾î·¯ºíÀÇ ÅëÇÕ µîÀÔ´Ï´Ù. Á¶±â Áø´Ü ¹× ÁøÇà ¿¹ÃøÀ» À§ÇÑ À¯ÀüÀÚ ¸¶Ä¿¿¡ ÃÊÁ¡À» ¸ÂÃá ¿¬±¸´Â ȹ±âÀûÀÎ ÅëÂû·ÂÀ» Á¦°øÇÒ ¼ö ÀÖ½À´Ï´Ù. Àü¹ÝÀûÀ¸·Î ¸²ÇÁºÎÁ¾ Áø´Ü ½ÃÀåÀº ¿ªµ¿ÀûÀÎ ½ÃÀåÀ̸ç, ±â¼ú ¹ßÀü°ú ¼¼°è º¸°Ç ³ë·ÂÀÇ È°¼ºÈ­·Î ÀÎÇØ Å« ¼ºÀå ±âȸ¸¦ Á¦°øÇϰí ÀÖÁö¸¸, ±× ÀáÀç·ÂÀ» ÃæºÐÈ÷ ¹ßÈÖÇϱâ À§Çؼ­´Â ºñ¿ë°ú ÀÎÇÁ¶ó Ãø¸é¿¡¼­ Å« °úÁ¦¸¦ ±Øº¹ÇØ¾ß ÇÕ´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁØ ¿¬µµ(2023³â) 3,248¸¸ ´Þ·¯
¿¹Ãø ¿¬µµ(2024³â) 3,546¸¸ ´Þ·¯
¿¹Ãø ¿¬µµ(2030³â) 6,040¸¸ ´Þ·¯
CAGR(%) 9.26%

½ÃÀå ¿ªÇÐ: ºü¸£°Ô ÁøÈ­ÇÏ´Â ¸²ÇÁºÎÁ¾ Áø´Ü¾à ½ÃÀå ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® °ø°³

¸²ÇÁºÎÁ¾ Áø´Ü ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ë¿¡ ÀÇÇØ º¯È­Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ ÁøÈ­¸¦ ÀÌÇØÇÔÀ¸·Î½á ±â¾÷Àº Á¤º¸¿¡ ÀÔ°¢ÇÑ ÅõÀÚ °áÁ¤, Àü·«Àû ÀÇ»ç°áÁ¤, »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Æ÷ÂøÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Æ®·»µå¸¦ Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ ¿ÏÈ­Çϰí, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë ¹× ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ¸²ÇÁ ºÎÁ¾ÀÇ À¯º´·ü Áõ°¡
    • ½ÉÇ÷°ü Áúȯ°ú ¾Ï Áõ°¡
    • ±â¼úÀûÀ¸·Î Áøº¸µÈ 3Â÷¿ø ¿µ»ó ½Ã½ºÅÛ Ã¤Åà Áõ°¡
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ¿µ»ó Áø´Ü ½Ã½ºÅÛÀÇ ³ôÀº ºñ¿ë
  • ½ÃÀå ±âȸ
    • »õ·Î¿î Áø´Ü ¹æ½Ä°ú °°Àº ±â¼ú ¹ßÀü
    • ¿¬±¸ °³¹ß ÅõÀÚ ¹× ÀÚ±Ý Áõ°¡
  • ½ÃÀå °úÁ¦
    • ¸²ÇÁ ºÎÁ¾ÀÇ Á¶±â Áø´ÜÀÇ ¾î·Á¿ò

Portre's Five Forces: ¸²ÇÁºÎÁ¾ Áø´ÜÁ¦ ½ÃÀå Ž»öÀ» À§ÇÑ Àü·« µµ±¸

Portre's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ½ÃÀå »óȲ°æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. Portre's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÇ °æÀï·ÂÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ Ž»öÇÒ ¼ö ÀÖ´Â ¸íÈ®ÇÑ ¹æ¹ýÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÅëÂû·ÂÀ» ÅëÇØ ±â¾÷Àº °­Á¡À» Ȱ¿ëÇϰí, ¾àÁ¡À» ÇØ°áÇϰí, ÀáÀçÀûÀÎ µµÀüÀ» ÇÇÇϰí, º¸´Ù °­·ÂÇÑ ½ÃÀå Æ÷Áö¼Å´×À» È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : ¸²ÇÁºÎÁ¾ Áø´ÜÁ¦ ½ÃÀåÀÇ ¿ÜºÎ ¿µÇâ ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº ¸²ÇÁºÎÁ¾ Áø´Ü ÀǾàǰ ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀο¡ ´ëÇÑ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇϸç, PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀû À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£µµ, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¼±Á¦ÀûÀÌ°í ´Éµ¿ÀûÀÎ ÀÇ»ç°áÁ¤À» ³»¸± Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® ¸²ÇÁºÎÁ¾ Áø´ÜÁ¦ ½ÃÀå¿¡¼­°æÀï ±¸µµ ÆÄ¾Ç

¸²ÇÁºÎÁ¾ Áø´Ü¾à ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¼öÀÍ, °í°´ ±â¹Ý, ¼ºÀå·ü°ú °°Àº ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀïÀû À§Ä¡¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®Àº ½ÃÀåÀÇ ÁýÁßÈ­, ´ÜÆíÈ­ ¹× ÅëÇÕ Ãß¼¼¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖÀ¸¸ç, °ø±Þ¾÷ü´Â Ä¡¿­ÇÑ °æÀï ¼Ó¿¡¼­ ÀÚ½ÅÀÇ ÀÔÁö¸¦ °­È­ÇÒ ¼ö ÀÖ´Â Àü·«Àû ÀÇ»ç°áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ ÅëÂû·ÂÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º ¸²ÇÁºÎÁ¾ Áø´ÜÁ¦ ½ÃÀå¿¡¼­°ø±Þ¾÷ü ¼º°ú Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â ¸²ÇÁºÎÁ¾ Áø´Ü ÀǾàǰ ½ÃÀå¿¡¼­ °ø±Þ¾÷ü¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº º¥´õÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±â¹ÝÀ¸·Î Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ºÎÇÕÇÏ´Â Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖÀ¸¸ç, 4°³ÀÇ »çºÐ¸éÀ¸·Î º¥´õ¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ¼¼ºÐÈ­ÇÏ¿© Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù. Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù.

Àü·« ºÐ¼® ¹× Ãßõ ¸²ÇÁºÎÁ¾ Áø´ÜÁ¦ ½ÃÀå¿¡¼­ ¼º°øÇϱâ À§ÇÑ Àü·« ºÐ¼® ¹× Ãßõ

¸²ÇÁºÎÁ¾ Áø´ÜÁ¦ ½ÃÀå Àü·« ºÐ¼®Àº ¼¼°è ½ÃÀå¿¡¼­ ÀÔÁö¸¦ °­È­ÇϰíÀÚ ÇÏ´Â ±â¾÷¿¡°Ô ÇʼöÀûÀÔ´Ï´Ù. ÁÖ¿ä ÀÚ¿ø, ¿ª·® ¹× ¼º°ú ÁöÇ¥¸¦ °ËÅäÇÔÀ¸·Î½á ±â¾÷Àº ¼ºÀå ±âȸ¸¦ ½Äº°ÇÏ°í °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù ¹æ½ÄÀ» ÅëÇØ °æÀï ȯ°æÀÇ µµÀüÀ» ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö ÀÖµµ·Ï ÁغñÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â ½ÃÀå¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõµµ : ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·Â Æò°¡.

2. ½ÃÀå °³Ã´µµ: ½ÅÈï ½ÃÀå¿¡¼­ÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇϰí, ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡Çϸç, ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù°¢È­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä ¹ßÀü, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú ¹ßÀü µîÀ» °ËÅäÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÷´Ü ±â¼ú, ¿¬±¸ °³¹ß Ȱµ¿ ¹× Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

ÀÌÇØ°ü°èÀÚµéÀÌ ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖµµ·Ï ´ÙÀ½°ú °°Àº Áß¿äÇÑ Áú¹®¿¡ ´ëÇÑ ´äº¯µµ Á¦°øÇÕ´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå Àü¸ÁÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹®, Áö¿ªÀº?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5.º¥´õ ½ÃÀå ÁøÀÔ ¹× ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ±âȸ
    • °úÁ¦
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • PorterÀÇ Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡
    • °æÁ¦
    • »çȸ
    • ±â¼ú
    • ¹ý·ü
    • ȯ°æ

Á¦6Àå ¸²ÇÁºÎÁ¾ Áø´Ü ½ÃÀå : ±â¼úº°

  • Bioimpedance Analysis
  • Computed Tomography
  • Lymphoscintigraphy
  • Magnetic Resonance Imaging
  • Near-Infrared Fluorescence Imaging
  • Ultrasound Imaging
  • X-Ray Lymphography

Á¦7Àå ¸²ÇÁºÎÁ¾ Áø´Ü ½ÃÀå : Áúȯº°

  • ¾Ï
  • ½ÉÇ÷°ü Áúȯ
  • ¿°Áõ¼º Áúȯ

Á¦8Àå ¸²ÇÁºÎÁ¾ Áø´Ü ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

  • Áø´Ü¼¾ÅÍ
  • º´¿ø
  • ¿¬±¸ ¹× Çмú±â°ü

Á¦9Àå ¾Æ¸Þ¸®Ä«ÀÇ ¸²ÇÁºÎÁ¾ Áø´Ü ½ÃÀå

  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦10Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ¸²ÇÁºÎÁ¾ Áø´Ü ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦11Àå À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ¸²ÇÁºÎÁ¾ Áø´Ü ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
  • ¿µ±¹

Á¦12Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼® 2023
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º, 2023
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®
  • Àü·« ºÐ¼®°ú Á¦¾È

±â¾÷ ¸®½ºÆ®

  • Canon, Inc.
  • Curadel, LLC
  • Esaote SPA
  • Essity Medical Solutions
  • Fluoptics
  • General Electric Company
  • ImpediMed Inc.
  • Julius Zorn GmbH
  • Mindray Medical International, Ltd.
  • Mitaka USA, Inc.
  • Neusoft Corporation
  • Shimadzu Corporation
  • Siemens Healthineers AG
  • Stryker Corporation
  • United Imaging Healthcare Co., Ltd.
LSH

The Lymphedema Diagnostics Market was valued at USD 32.48 million in 2023, expected to reach USD 35.46 million in 2024, and is projected to grow at a CAGR of 9.26%, to USD 60.40 million by 2030.

Lymphedema diagnostics encompass a range of methods used to identify and assess lymphatic system dysfunction, characterized by the abnormal swelling of body tissues due to lymph accumulation. This market's scope is expansive, covering technologies such as imaging tests (ultrasound, MRI), bioimpedance spectroscopy, and lymphoscintigraphy. The necessity for these diagnostics stems from increasing lymphedema prevalence due to rising cases of cancer treatments, obesity, and aging populations, necessitating precise and early diagnosis for effective management. End-use includes hospitals, diagnostic centers, and home-care settings, showcasing varied application arenas. Key growth factors driving the market include advances in diagnostic technologies, increasing healthcare awareness, and improved access to healthcare facilities. Opportunities exist in the integration of AI and machine learning for enhanced diagnostic accuracy and the development of portable and user-friendly devices, catering particularly to home-care settings and regions with limited healthcare infrastructure. Companies might benefit from exploring partnerships with technology firms to innovate diagnostic solutions and leveraging telemedicine for wider market reach. However, challenges such as high costs of advanced diagnostic equipment, lack of standardization in detection methods, and a limited number of trained healthcare professionals act as significant barriers to market expansion. The market also faces regulatory scrutiny concerning the safety and efficacy of diagnostic methods. The best areas for innovation include personalized medicine approaches, improving non-invasive diagnostic accuracy, and integrating sensors and wearables for continuous monitoring. Research that focuses on genetic markers for early identification and progression prediction could provide breakthrough insights. Overall, the lymphedema diagnostics market is dynamic, with substantial opportunities for growth driven by technological advancements and increased global health initiatives, though it requires overcoming significant cost and infrastructural challenges to realize its full potential.

KEY MARKET STATISTICS
Base Year [2023] USD 32.48 million
Estimated Year [2024] USD 35.46 million
Forecast Year [2030] USD 60.40 million
CAGR (%) 9.26%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Lymphedema Diagnostics Market

The Lymphedema Diagnostics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of lymphedema
    • Increasing incidences of cardiovascular diseases and cancer
    • Rising adoption of technologically advanced three dimensional imaging systems
  • Market Restraints
    • High Cost of diagnostic imaging systems
  • Market Opportunities
    • Advancement in technology such as new diagnostic modalities
    • Increasing investment and funds in research and developmen
  • Market Challenges
    • Difficulties in early stage diagnosis of lymphedema

Porter's Five Forces: A Strategic Tool for Navigating the Lymphedema Diagnostics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Lymphedema Diagnostics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Lymphedema Diagnostics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Lymphedema Diagnostics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Lymphedema Diagnostics Market

A detailed market share analysis in the Lymphedema Diagnostics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Lymphedema Diagnostics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Lymphedema Diagnostics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Lymphedema Diagnostics Market

A strategic analysis of the Lymphedema Diagnostics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Lymphedema Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Canon, Inc., Curadel, LLC, Esaote SPA, Essity Medical Solutions, Fluoptics, General Electric Company, ImpediMed Inc., Julius Zorn GmbH, Mindray Medical International, Ltd., Mitaka USA, Inc., Neusoft Corporation, Shimadzu Corporation, Siemens Healthineers AG, Stryker Corporation, and United Imaging Healthcare Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Lymphedema Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Technology, market is studied across Bioimpedance Analysis, Computed Tomography, Lymphoscintigraphy, Magnetic Resonance Imaging, Near-Infrared Fluorescence Imaging, Ultrasound Imaging, and X-Ray Lymphography.
  • Based on Disease, market is studied across Cancer, Cardiovascular Disease, and Inflammatory Diseases.
  • Based on End User, market is studied across Diagnostic Centers, Hospitals, and Research & Academic Institutes.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of lymphedema
      • 5.1.1.2. Increasing incidences of cardiovascular diseases and cancer
      • 5.1.1.3. Rising adoption of technologically advanced three dimensional imaging systems
    • 5.1.2. Restraints
      • 5.1.2.1. High Cost of diagnostic imaging systems
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancement in technology such as new diagnostic modalities
      • 5.1.3.2. Increasing investment and funds in research and developmen
    • 5.1.4. Challenges
      • 5.1.4.1. Difficulties in early stage diagnosis of lymphedema
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Lymphedema Diagnostics Market, by Technology

  • 6.1. Introduction
  • 6.2. Bioimpedance Analysis
  • 6.3. Computed Tomography
  • 6.4. Lymphoscintigraphy
  • 6.5. Magnetic Resonance Imaging
  • 6.6. Near-Infrared Fluorescence Imaging
  • 6.7. Ultrasound Imaging
  • 6.8. X-Ray Lymphography

7. Lymphedema Diagnostics Market, by Disease

  • 7.1. Introduction
  • 7.2. Cancer
  • 7.3. Cardiovascular Disease
  • 7.4. Inflammatory Diseases

8. Lymphedema Diagnostics Market, by End User

  • 8.1. Introduction
  • 8.2. Diagnostic Centers
  • 8.3. Hospitals
  • 8.4. Research & Academic Institutes

9. Americas Lymphedema Diagnostics Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Lymphedema Diagnostics Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Lymphedema Diagnostics Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Canon, Inc.
  • 2. Curadel, LLC
  • 3. Esaote SPA
  • 4. Essity Medical Solutions
  • 5. Fluoptics
  • 6. General Electric Company
  • 7. ImpediMed Inc.
  • 8. Julius Zorn GmbH
  • 9. Mindray Medical International, Ltd.
  • 10. Mitaka USA, Inc.
  • 11. Neusoft Corporation
  • 12. Shimadzu Corporation
  • 13. Siemens Healthineers AG
  • 14. Stryker Corporation
  • 15. United Imaging Healthcare Co., Ltd.
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦